Evaluating the Feasibility of VR for Pediatric Renal Biopsies

Sponsor
University of California, San Francisco (Other)
Overall Status
Recruiting
CT.gov ID
NCT05267704
Collaborator
(none)
20
1
1
6
3.3

Study Details

Study Description

Brief Summary

The purpose of this study is to assess the use of virtual reality (VR) as an adjunct or alternative to pharmacologic sedation in pediatric patients undergoing renal biopsy.

Condition or Disease Intervention/Treatment Phase
  • Device: Samsung Gear Virtual Reality Headset
N/A

Detailed Description

Children aged 5-17 scheduled for renal biopsy will be offered the option to use a virtual reality (VR) headset that displays an interactive game as part of their renal biopsy experience. The standard of care of sedation medications will still be available to patients who are unable to complete the procedure with only the VR headset without pharmacologic sedation. Pain and anxiety will be monitored continuously using validated scales by a pediatric hospitalist and sedation nurse. These providers, as well as patients and parents, may ask for additional medications for adequate analgesia and anxiolysis.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Evaluating the Feasibility of Virtual Reality for Procedural Sedation in Pediatric Renal Biopsy Patients
Anticipated Study Start Date :
Aug 1, 2022
Anticipated Primary Completion Date :
Jan 31, 2023
Anticipated Study Completion Date :
Jan 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: VR Arm

Pediatric patients age 5-17 using the VR headset during renal biopsy.

Device: Samsung Gear Virtual Reality Headset
VR headset displaying preselected game during renal biopsy

Outcome Measures

Primary Outcome Measures

  1. Acceptability of VR to Patients/Families [From arrival to procedural room to completion of procedure (~30 minutes)]

    Acceptability of VR as non-pharmacologic sedation based on a team-made Likert scale survey given to patients, parents, and providers (Likert scale, with 1 = "strongly disagree" as most dissatisfied with VR experience and 5 = "strongly agree" as most satisfied with VR experience and a better perceived outcome

Secondary Outcome Measures

  1. Pre- and Post-Procedural Pain (Change in Observation Scale of Behavioral Distress Scale) [From arrival to procedural room to completion of procedure (~30 minutes), at 15-second intervals]

    Pain as recorded on Observation Scale of Behavioral Distress (OSBD 11 point behavioral scale rating the number and intensity of distress behaviors demonstrated before/during/after the procedure in 15-second intervals; higher scores and intensity of distress behaviors indicate worse pain)

  2. Pre- and Post-Procedural Anxiety (Change in Childhood Anxiety Meter) [From arrival to procedural room to completion of procedure (~30 minutes)]

    Anxiety as recorded on Childhood Anxiety Meter (CAM 0-10 scale, using analogy of mercury thermometer to ask children to rate level of anxiety, with higher score indicating more anxiety)

  3. Pre- and Post-Procedural Anxiety (Change in Child Fear Scale) [From arrival to procedural room to completion of procedure (~30 minutes)]

    Children's Fear Scale (CFS 0-4 scale, visual face scale correlated with 0-4 numeric scale, with 4 being highest fear/anxiety related to procedure)

  4. Patient, Parent, and Provider Satisfaction (Post-procedure) [From arrival to procedural room to completion of procedure (~30 minutes)]

    Patient, parent, and provider satisfaction as assessed on 4-question Likert scale (0 to 5, with 5 being high satisfaction) survey

  5. Total Dose of Sedation Needed [From arrival to procedural room to completion of procedure (~30 minutes)]

    Total dose (mg/kg) of pharmacologic sedation needed to complete renal biopsy with adequate patient analgesia, anxiolysis, and comfort

Eligibility Criteria

Criteria

Ages Eligible for Study:
5 Years to 17 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Patients age 5-17 receiving a renal biopsy at the University of California, San Francisco (UCSF) Benioff Children's Hospital
Exclusion Criteria:
  • Patients who cannot lie supine for their renal biopsy will be excluded from the study

  • Patients with injuries to the head/face that would prohibit wearing a headset

  • Patients with loss of consciousness, altered mental status, life-threatening injuries/illness or multi-trauma

  • Patients with open skin, lice, scabies, or other infectious skin conditions on the head/face

  • Patients with a history of or current symptoms of vertigo

  • Patients who are blind

  • Patients with significant developmental or cognitive delays who may not be able to engage with or tolerate the virtual reality environment, as determined by their parent/caregiver

  • Patients on whom the VR headset does not fit appropriately

Contacts and Locations

Locations

Site City State Country Postal Code
1 UCSF Benioff Children's Hospital San Francisco California United States 94143

Sponsors and Collaborators

  • University of California, San Francisco

Investigators

  • Principal Investigator: Justin Libaw, MD, MPH, University of California, San Francisco

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

Responsible Party:
University of California, San Francisco
ClinicalTrials.gov Identifier:
NCT05267704
Other Study ID Numbers:
  • 21-35095
First Posted:
Mar 4, 2022
Last Update Posted:
Jul 7, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
Yes
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 7, 2022